BR112019015721A2 - Inibidores de tiol isomerases e uso dos mesmos - Google Patents
Inibidores de tiol isomerases e uso dos mesmos Download PDFInfo
- Publication number
- BR112019015721A2 BR112019015721A2 BR112019015721-2A BR112019015721A BR112019015721A2 BR 112019015721 A2 BR112019015721 A2 BR 112019015721A2 BR 112019015721 A BR112019015721 A BR 112019015721A BR 112019015721 A2 BR112019015721 A2 BR 112019015721A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- zafirlukast
- isomerase
- extracellular
- thiol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451858P | 2017-01-30 | 2017-01-30 | |
| US62/451,858 | 2017-01-30 | ||
| PCT/US2018/015694 WO2018140858A1 (en) | 2017-01-30 | 2018-01-29 | Thiol isomerases inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019015721A2 true BR112019015721A2 (pt) | 2020-03-24 |
Family
ID=62978426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019015721-2A BR112019015721A2 (pt) | 2017-01-30 | 2018-01-29 | Inibidores de tiol isomerases e uso dos mesmos |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11872210B2 (https=) |
| EP (1) | EP3585809B1 (https=) |
| JP (3) | JP7272655B2 (https=) |
| BR (1) | BR112019015721A2 (https=) |
| CA (2) | CA3282526A1 (https=) |
| WO (1) | WO2018140858A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019164874A1 (en) | 2018-02-20 | 2019-08-29 | Western New England University | Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases |
| CN113289020B (zh) * | 2021-05-17 | 2023-04-18 | 福州大学 | 蛋白质二硫键异构酶小分子抑制剂及其应用 |
| AU2022276190A1 (en) | 2021-05-19 | 2024-01-18 | Quercis Pharma AG | Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis |
| WO2023214391A1 (en) * | 2022-05-06 | 2023-11-09 | Quercis Pharma AG | Method for treating cancers and neurological diseases using quercetin-containing compositions |
| CN120187701A (zh) * | 2022-08-19 | 2025-06-20 | 西新英格兰大学 | 硫醇异构酶抑制剂及其制备方法和使用方法 |
| WO2025094946A1 (ja) * | 2023-10-30 | 2025-05-08 | 国立大学法人東海国立大学機構 | 抗体又はその抗原結合性断片、がんの治療用キット、及びがんの治療用組成物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA825413B (en) | 1981-08-26 | 1983-06-29 | Pfizer | Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them |
| GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| US4985465A (en) | 1989-07-14 | 1991-01-15 | Hendler Sheldon S | Method for inhibiting viral and retroviral infections |
| US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| GB9027018D0 (en) | 1990-12-12 | 1991-01-30 | Ici Plc | Heterocyclic compounds |
| IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| GB9723985D0 (en) | 1997-11-14 | 1998-01-14 | Zeneca Ltd | Pharmaceutical compositions |
| GB9726735D0 (en) | 1997-12-18 | 1998-02-18 | Zeneca Ltd | Pharmaceutical compositions |
| IL139243A0 (en) * | 2000-10-24 | 2001-11-25 | Internat Specialty Products Is | Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof |
| ES2333979T3 (es) * | 2004-11-22 | 2010-03-03 | Eli Lilly And Company | Potenciadores de los receptores del glutamato. |
| KR100649009B1 (ko) | 2004-12-30 | 2006-11-27 | 동부일렉트로닉스 주식회사 | 시모스 이미지 센서의 광감지 소자 및 그의 제조방법 |
| EP3087969B1 (en) | 2005-05-20 | 2021-06-30 | Jack L. Arbiser | Proteasome inhibitors and uses thereof |
| WO2007070875A1 (en) | 2005-12-15 | 2007-06-21 | Aerosol Science Laboratories, Inc. | Treatment of active infections and related compositions |
| US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| DE102007001804A1 (de) | 2007-01-12 | 2008-07-17 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen |
| EP2269076A4 (en) | 2008-03-14 | 2011-04-06 | Nat Jewish Health | METHOD FOR DETERMINING THE RECOMMENDATION FOR TREATMENT WITH LEUKOTRIA MODIFIERS |
| WO2009152454A1 (en) | 2008-06-12 | 2009-12-17 | The Johns Hopkins University | Methods for treating or preventing brain infections |
| WO2013055674A1 (en) | 2011-10-10 | 2013-04-18 | The University Of Toledo | Method for treating infections |
| US9730921B2 (en) | 2012-03-27 | 2017-08-15 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| CN103505731A (zh) | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| US9616056B2 (en) | 2013-03-15 | 2017-04-11 | Institute For Cancer Research | Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma |
| WO2014175253A1 (ja) * | 2013-04-22 | 2014-10-30 | 株式会社栃木臨床病理研究所 | 抗腫瘍剤 |
| US20160145209A1 (en) * | 2013-06-21 | 2016-05-26 | The Broad Institute, Inc. | Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase |
| GB201321089D0 (en) * | 2013-11-29 | 2014-01-15 | Univ East London | Leukotriene receptor antagonists and their derivatives for use as antibacterial agents |
| WO2016118639A1 (en) * | 2015-01-20 | 2016-07-28 | The Trustees Of Columbia University In The City Of New York | Small molecule oxidizers of pdi and their use |
| JP6528314B2 (ja) * | 2015-03-20 | 2019-06-12 | 国立大学法人山口大学 | Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤 |
-
2018
- 2018-01-29 US US16/480,844 patent/US11872210B2/en active Active
- 2018-01-29 BR BR112019015721-2A patent/BR112019015721A2/pt unknown
- 2018-01-29 WO PCT/US2018/015694 patent/WO2018140858A1/en not_active Ceased
- 2018-01-29 CA CA3282526A patent/CA3282526A1/en active Pending
- 2018-01-29 CA CA3052071A patent/CA3052071A1/en active Pending
- 2018-01-29 JP JP2019562217A patent/JP7272655B2/ja active Active
- 2018-01-29 EP EP18745381.6A patent/EP3585809B1/en active Active
-
2022
- 2022-12-14 JP JP2022199341A patent/JP2023030014A/ja active Pending
-
2023
- 2023-12-13 US US18/537,947 patent/US20240108600A1/en active Pending
-
2024
- 2024-08-13 JP JP2024134797A patent/JP2024161023A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7272655B2 (ja) | 2023-05-12 |
| EP3585809B1 (en) | 2025-07-02 |
| EP3585809A1 (en) | 2020-01-01 |
| EP3585809A4 (en) | 2021-02-24 |
| US20210008032A1 (en) | 2021-01-14 |
| WO2018140858A1 (en) | 2018-08-02 |
| CA3282526A1 (en) | 2025-10-30 |
| CA3052071A1 (en) | 2018-08-02 |
| US20240108600A1 (en) | 2024-04-04 |
| JP2023030014A (ja) | 2023-03-07 |
| JP2020514411A (ja) | 2020-05-21 |
| US11872210B2 (en) | 2024-01-16 |
| JP2024161023A (ja) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019015721A2 (pt) | Inibidores de tiol isomerases e uso dos mesmos | |
| US20230142627A1 (en) | Pharmaceutical compositions and methods | |
| Jang et al. | Hydrogen sulfide treatment induces angiogenesis after cerebral ischemia | |
| JP2014058561A (ja) | 癌を処置するための治療剤の組合せ | |
| KR20210043760A (ko) | 빈혈 치료용 조성물 및 치료방법 | |
| Liu et al. | Morroniside enhances angiogenesis and improves cardiac function following acute myocardial infarction in rats | |
| CN110325190A (zh) | 增加血管密度的方法 | |
| JP2009536153A (ja) | 癌を処置するための治療剤の組合せ | |
| KR20220131224A (ko) | 허혈-재관류 손상 및/또는 폐 손상을 치료하기 위한 화합물, 조성물 및 방법 | |
| EP3998076A1 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| Esberg et al. | The oxygen radical generator pyrogallol impairs cardiomyocyte contractile function via a superoxide and p38 MAP kinase-dependent pathway: protection by anisodamine and tetramethylpyrazine | |
| US12168019B1 (en) | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | |
| KR101497868B1 (ko) | 리모닌을 유효성분으로 포함하는 혈관근육세포의 증식과 관련된 질환의 예방 및 치료용 약제학적 조성물 | |
| US20190290729A1 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| JP7603011B2 (ja) | 置換縮合イミダゾール誘導体並びに鎌状赤血球症及び関連する合併症を処置する方法 | |
| AU2017406103A1 (en) | Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity | |
| WO2017046229A1 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| KR101599259B1 (ko) | 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물 | |
| Imtiaz et al. | Selection of lansoprazole from an | |
| HK40091747A (zh) | 用於治疗癌症的组合疗法 | |
| CN107397749A (zh) | 莲花掌苷的新用途 | |
| Uppala et al. | Antiretroviral Therapy: What to Look Out For! | |
| US20160128999A1 (en) | Masitinib for treating hepatic cancer | |
| EP3400233A1 (en) | Pharmaceutical compositions and methods | |
| KR20160096842A (ko) | Ｍａｚ５１을 포함하는 신경아교종 치료용 약학조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |